United Therapeutics CORP Form 4 insider transactions

Martine A. Rothblatt, Chairperson & CEO of United Therapeutics, exercised stock options and sold an equivalent number of shares under a pre-arranged 10b5-1 trading plan.

United Therapeutics' EVP & General Counsel, Paul A. Mahon, exercised stock options and subsequently sold 8,300 shares of common stock under a pre-arranged 10b5-1 plan.

United Therapeutics CEO Martine Rothblatt exercised stock options and sold shares as part of a pre-arranged 10b5-1 trading plan.

United Therapeutics CEO Martine Rothblatt exercised stock options and sold resulting shares under a pre-arranged 10b5-1 trading plan.

United Therapeutics Corp's President and COO, Michael Benkowitz, reported the vesting of restricted stock units and related share transactions, including tax withholdings and an Employee Stock Purchase Plan acquisition.

United Therapeutics CFO James Edgemond reported the vesting of restricted stock units and subsequent tax-related share withholdings, alongside an Employee Stock Purchase Plan acquisition.

United Therapeutics' EVP & General Counsel, Paul A. Mahon, reported the vesting and conversion of restricted stock units into common stock, with a portion withheld for taxes.

Martine A. Rothblatt, Chairperson and CEO of United Therapeutics Corp, reported the vesting of restricted stock units and subsequent share adjustments for tax purposes.

United Therapeutics Director Jan Malcolm sold 45 shares of common stock for $533.51 per share under a pre-arranged 10b5-1 trading plan.

Judy D. Olian, a director at United Therapeutics Corp, sold 200 shares of common stock for $535.44 per share under a pre-arranged 10b5-1 plan.

United Therapeutics CEO Martine Rothblatt exercised stock options and sold resulting shares as part of a pre-arranged 10b5-1 trading plan.

United Therapeutics Corp's Chairperson & CEO, Martine A. Rothblatt, executed a planned sale of common stock following option exercise.

United Therapeutics' EVP & General Counsel, Paul A. Mahon, exercised stock options and subsequently sold 8,300 shares of common stock under a pre-arranged 10b5-1 plan.

United Therapeutics CEO Martine A. Rothblatt exercised stock options and sold 9,500 shares of common stock as part of a pre-arranged 10b5-1 trading plan.

Ray Kurzweil, a director at United Therapeutics Corp, exercised stock options and subsequently sold an equal number of common shares.

United Therapeutics Director Tommy G. Thompson exercised stock options and subsequently sold an equal number of common shares for a significant profit.

United Therapeutics Director Christopher Causey exercised stock options and sold shares totaling 20 units under a pre-arranged 10b5-1 trading plan.

Martine A. Rothblatt, Chairperson and CEO of United Therapeutics Corp, exercised stock options and sold an equivalent number of shares under a pre-arranged 10b5-1 trading plan.

United Therapeutics CEO Martine Rothblatt exercised stock options and sold the resulting shares as part of a pre-arranged 10b5-1 trading plan.

United Therapeutics Director Judy D. Olian sold 200 shares of common stock for $509.55 per share under a pre-arranged 10b5-1 trading plan.

United Therapeutics' EVP & General Counsel, Paul A. Mahon, was awarded performance-based stock options and restricted stock units on March 15, 2023, contingent on future company performance.

United Therapeutics CEO Martine Rothblatt has earned significant performance-based stock options and restricted stock units tied to 2023-2025 financial and clinical goals.

United Therapeutics' President and COO, Michael Benkowitz, has earned significant performance-based stock options and restricted stock units following the achievement of multi-year targets.

United Therapeutics CFO James Edgemond earned significant performance-based stock options and restricted stock units following the achievement of multi-year company targets.

Christopher Causey, a Director at United Therapeutics Corp, executed a pre-planned sale of 1,000 common shares following the exercise of stock options.

United Therapeutics' President and COO Michael Benkowitz completed the sale of 14,440 shares of common stock through a pre-arranged 10b5-1 trading plan.

United Therapeutics' EVP & General Counsel, Paul A. Mahon, exercised stock options and subsequently sold the resulting shares under a pre-arranged 10b5-1 plan.

United Therapeutics COO Michael Benkowitz sold shares acquired through option exercises under a pre-arranged Rule 10b5-1 trading plan.

United Therapeutics' EVP & General Counsel, Paul A. Mahon, exercised stock options and subsequently sold 8,300 shares of common stock.

United Therapeutics Director Jan Malcolm sold 50 shares of common stock for $474.23 per share under a pre-arranged 10b5-1 trading plan.